GlassScriptPhysician profile
Avantica Gondi
NPI 1063673812
$4,706.96
in general payments reported to CMS, 2019-2025
27 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $592 · 2020: $1,028 · 2021: $999 · 2022: $762 · 2023: $512 · 2024: $376 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,325.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,120.92 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $617.85 | 2021-2025 | |
| Lilly USA, LLC | $520.31 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $493.25 | 2019-2023 | Jardiance, Synjardy |
| Novo Nordisk INC | $408.13 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $289.92 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Pfizer INC. | $199.09 | 2019-2022 | |
| Allergan, INC. | $169.45 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $150.60 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $132.49 | 2022-2025 | |
| Amgen INC. | $86.73 | 2019-2022 | |
| Dexcom, INC. | $73.21 | 2021-2024 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $56.38 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.88 | 2022 | |
| Esperion Therapeutics, INC. | $43.52 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.16 | 2024 | Xifaxan |
| Shield Therapeutics INC | $34.58 | 2024-2025 | |
| Abbott Laboratories | $31.65 | 2021-2022 | |
| Circassia INC. | $31.53 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $25.70 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.53 | 2021 | |
| Merck Sharp & Dohme LLC | $24.08 | 2021 | |
| Global Blood Therapeutics, INC. | $19.38 | 2020 | |
| Mylan Specialty L.P. | $18.45 | 2023 | Yupelri |
| Teva Pharmaceuticals USA, INC. | $16.76 | 2021 | |
| Polynovo North America LLC | $14.85 | 2025 | Novosorb Btm |
| Arbor Pharmaceuticals, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avantica Gondi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.